Xspray PharmaXspray Pharma informs that FDA has completed its inspection of NerPharMa’s manufacturing facility
Xspray Pharma AB (publ) (Nasdaq Stockholm: XSPRAY) has been informed by its contract manufacturing NerPharMa that the U.S. Food and Drug Administration (FDA) has completed its follow-up inspection of NerPharMa’s manufacturing facility in Italy. The FDA is expected to determine the facility’s inspection classification within 90 days.
Consistent with the FDA inspection procedure, at the conclusion of the inspection, the FDA issued a Form FDA 483 containing observations to which NerPharMa will provide its written response by December 9, 2026. Observations are not graded by the FDA individually and it is not currently possible to determine what the outcome will be of the FDA’s holistic assessment of the inspection and the manufacturer’s actions. Nerpharma has confirmed that none of the observations specifically refer to Xspray’s manufacturing lines or the manufacturing of Dasynoc® or Nilopki®.
The FDA is expected to determine the facility’s inspection classification within 90 days, i.e. around mid-February 2027.
NerPharMa has confirmed that the work to address the observations is already under way. NerPharMa is fully committed to address the observations and will submit its response to the FDA by December 9, 2026.
“While we emphasize that the FDA has not yet reached a decision regarding the manufacturer's cGMP status, we are encouraged by NerPharMa’s commitment and pleased that the FDA process is progressing with a clear timeframe ahead. We will continue to work closely with NerPharMa and support them where appropriate. We remain focused on completing the work required to resubmit the NDAs for Dasynoc and Nilopki and anticipate the FDA's decision regarding NerPharMa,” says Blake Leitch, CEO of Xspray Pharma.
The plan to resubmit both NDAs during the fourth quarter of 2026 remains unchanged.
Xspray Pharma will inform the market when material new information is available.
Bilagor & Media
0 kommentarer
Kommentera nyheten
När du kommenterar ett pressmeddelande publiceras din kommentar även i en speglad tråd under Börssnack så att alla i forumet kan delta i diskussionen!
Logga in eller skapa ett gratis konto för att kommentera nyheten!
